Overview

Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis

Status:
Recruiting

Trial end date:
2022-09-01

Target enrollment:

Participant gender:

Summary

Antimicrobial treatment could be beneficial in patients with ventilator-associated tracheobronchitis (VAT). The hypothesis of this study is that antibiotic treatment for VAT (3 or 7 days), compared with no antibiotic treatment, would reduce the incidence of transition from VAT to ventilator-associated pneumonia (VAP).

Phase:

Phase 4

Details

Lead Sponsor:

University Hospital, Lille

Collaborator:

Ministry of Health, France

Treatments:

Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antitubercular
Ceftriaxone
Ciprofloxacin
Imipenem
Linezolid